A pharmaceutical company that manufactures mifepristone has asked the Supreme Court of the United States to intervene after a lower court ruling restricted how the abortion pill can be distributed.

In an emergency filing, Danco Laboratories urged the court to lift a decision by the U.S. Court of Appeals for the Fifth Circuit that bars providers from dispensing the medication by mail.

The company argued the ruling has triggered widespread disruption across the healthcare system, affecting manufacturers, pharmacies, providers, and patients. Its attorneys said the situation creates “immediate confusion” and constitutes irreparable harm requiring urgent judicial relief.

The appeals court decision, which took effect immediately, temporarily blocks 2023 guidelines issued by the Food and Drug Administration that had expanded access to the drug under the administration of Joe Biden. The restrictions come as litigation continues and amid a broader regulatory review.

The latest legal challenge follows a similar case two years ago in which the Supreme Court unanimously rejected efforts to restrict mifepristone, ruling that the plaintiffs lacked legal standing.

The justices are now being asked to decide whether to pause the lower court’s ruling while the case proceeds.